References
- Limaye K. Psoriasis: an overview and update. Nurse Pract. 2015;40:23–26.
- Irimie M, Oanţă A, Irimie C, et al. Cardiovascular risk factors in patients with chronic plaque psoriasis: a case-control study on the Brasov county population. Acta Dermatovenerol Croat. 2015;23:28–35.
- Ahlehoff O, Gislason GH, Lindhardsen J, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One. 2011;256:e18125.
- Malkic Salihbegovic E, Hadzigrahic N, Cickusic A. Psoriasis and metabolic syndrome. Med Arch. 2015;69:85–87.
- Chiricozzi A, Raimondo A, Lembo S, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016;27:1–10.
- Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013;98:4899–997.
- Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–68.
- Aydin S. Three new players in energy regulation: preptin, adropin and irisin. Peptides. 2014;56:94–110.
- Gamas L, Matafome P, Seiça R. Irisin and myonectin regulation in the insulin resistant muscle: implications to adipose tissue: muscle crosstalk. J Diabetes Res. 2015;2015:359159.
- Chen N, Li Q, Liu J. Irisin, an exercise-induced myokine as a metabolic regulator: an updated narrative review. Diabetes Metab Res Rev. 2016;32:51–59.
- Roca-Rivada A, Castelo C, Sein L, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One. 2013;8:e60563.
- Panati K, Auneetha Y, Narala VR. Irisin/FNDC5 - an updated review . Eur Rev Med Pharmacol Sci. 2016;20:689–97.
- Zhang M, Chen P, Chen S, et al. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci. 2014;18:1567–72.
- Zhang Y, Mu Q, Zhou Z, et al. Protective effect of irisin on atherosclerosis via suppressing oxidized low density lipoprotein induced vascular inflammation and endothelial dysfunction. PLoS One. 2016;11:e0158038.
- Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoS One. 2014;9:e94235.
- Du XL, Jiang WX, Lv ZT. Lower circulating irisin level in patients with diabetes mellitus: a systematic review and meta-analysis. Horm Metab Res. 2016;48:644–52.
- Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res. Clin. Pract. 2013;100:96–101.
- Ebert T, Focke D, Petroff D, et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol. 2014;170:501–06.
- Shoukry A, Shalaby SM, El-Arabi Bdeer S, et al. Circulating serum irisin levels in obesity and type 2 diabetes mellitus. IUBMB Life. 2016;68:544–56.
- Huh JH, Ahn SV, Choi JH, et al. High serum irisin level as an independent predictor of diabetes mellitus: a longitudinal population-based study. Medicine (Baltimore). 2016;95:e3742.
- Crujeiras AB, Pardo M, Casanueva FF. Irisin: 'fat' or artefact. Clin Endocrinol (Oxf). 2015;82:467–74.
- Huh JY, Pangiatou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab Clin Exp.2012;61:1725–38.
- Timmons JA, Baar K, Davidsen PK, et al. Is irisin a human exercise gene? Nature. 2012;488:E9–10.
- Moreno-Navarette JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013;98:E769–78.
- Stengel A, Hofmann T, Goebel-Stengel M, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – correlation with body mass index. Peptides. 2013;39:125–30.
- Sanchiz-Gomar Lippi G, Mayero S, et al. Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes. 2012;4:196.
- Liu JJ, Wong MD, Toy WC. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:365–69.
- Baran A, Świderska M, Myśliwiec H, et al. Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels. J Dermatolog Treat. 2016. [Epub ahead of print]. doi: 10.1080/09546634.2016.1180340.